HOTH - Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

• Hoth Therapeutics ( NASDAQ: HOTH ) said on Tuesday it had signed an agreement with Altasciences to develop and manufacture the HT-TBI drug product formulation for the treatment and/or prevention of secondary brain injury.
• HT-TBI will be developed as a ready-to-use drug-device combination product for use in non-healthcare settings by patients and caregivers at risk for stroke/TBI, emergency healthcare professionals, and military personnel.
• "We are leveraging Altasciences' expertise to develop and manufacture novel parenteral formulations to achieve a formulation that requires no preparation or special storage requirements to ensure HT-TBI can be used anywhere in the field at the time a head injury or stroke occurs," the company said.

For further details see: